Partnership Announcement
Metrion Biosciences Limited (“Metrion”) and Enamine Ltd (“Enamine”) have joined forces to elevate Metrion’s High Throughput Screening (HTS) services. The collaboration between the specialist ion channel and cardiac safety screening contract research organization (CRO), Metrion, and the global leader in supplying small molecules and early drug discovery services, Enamine, aims to provide enhanced access to compound libraries for drug discovery projects.
Expanded Screening Capabilities
Metrion’s HTS services now incorporate Enamine’s extensive compound library collection, which includes both central nervous system (CNS) and ion channel-focused target libraries. This addition allows researchers to access a diverse range of screening sets, facilitating more flexible and efficient screening processes. Moreover, Enamine’s “analog-by-catalog” and “make-on-demand REAL libraries” offer rapid and cost-effective solutions for hit expansion and structure-activity relationship (SAR) studies.
Strategic Benefits and Expertise
The collaboration between Metrion and Enamine brings together specialist ion channel expertise with substantial HTS and hit-finding experience. By leveraging Metrion’s team of drug discovery scientists and Enamine’s high-quality screening libraries, clients gain access to a dedicated team that can assist in making strategic decisions for compound selection and screening. Gary Clark, Director of Screening Technologies at Metrion Biosciences, highlights the significance of this partnership in maximizing research and development (R&D) budgets effectively.
Additionally, Enamine’s Executive Vice President, Vladimir Ivanov, emphasizes their commitment to supporting drug discovery processes beyond compound libraries. Enamine offers comprehensive services, including hit resupply, analoging, and custom synthesis of advanced hits and leads, ensuring seamless support throughout the drug discovery journey.
Conclusion
The collaboration between Metrion Biosciences and Enamine represents a significant advancement in the field of drug discovery. By combining expertise and resources, the partnership aims to accelerate research efforts and facilitate the development of novel therapeutic compounds. Researchers and pharmaceutical companies can now benefit from enhanced screening capabilities and access to a diverse range of high-quality compound libraries, ultimately driving innovation and progress in the pharmaceutical industry.
